Welcome to our dedicated page for HeartBeam SEC filings (Ticker: BEATW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HeartBeam's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HeartBeam's regulatory disclosures and financial reporting.
HeartBeam, Inc. is a development-stage medical technology company focused on portable, cable‑free 12‑lead ECG systems for ambulatory cardiac monitoring. Its HeartBeam System, a credit card–sized 3D ECG device with cloud software and physician portal, received FDA clearance for arrhythmia assessment in December 2024 and for 12‑lead synthesis software in December 2025.
The company generated no revenue in 2025 and had 16 employees as of December 31, 2025, growing to 17 in early 2026 with the hire of a Chief Commercial Officer to lead commercialization. Management and the auditor highlight substantial doubt about HeartBeam’s ability to continue as a going concern, citing limited working capital and the need for additional financing, which may be dilutive.
HeartBeam plans a limited U.S. launch in early 2026 targeting concierge and preventive cardiology practices, while pursuing expanded indications such as heart attack detection, an extended‑wear 12‑lead patch, and AI‑based diagnostic algorithms. The company operates in a large, growing cardiac monitoring market and reports a broad patent portfolio, including 25 issued patents worldwide and multiple pending applications protecting its 3D ECG, patch, smartwatch and AI technologies.